S&P Futures
5,891.25 -5.00 (-0.08%) Dow Futures
43,133.00 -44.00 (-0.10%) Nasdaq Futures
20,497.00 -22.50 (-0.11%) Russell 2000 Futures
2,251.30 -4.20 (-0.19%) Crude Oil
70.54 -0.02 (-0.03%) Gold
2,737.10 -1.80 (-0.07%)
Alto Neuroscience, Inc. (ANRO)
After hours:
| Previous Close | 14.43 |
| Open | 14.58 |
| Bid | 13.53 x 1000 |
| Ask | 14.74 x 1000 |
| Day's Range | 14.09 - 14.85 |
| 52 Week Range | 7.91 - 24.00 |
| Volume | |
| Avg. Volume | 339,025 |
| Market Cap | 385.244M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.85 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.50 |
Simply Wall St.Alto Neuroscience Insiders Placed Bullish Bets Worth US$638.5k
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Insider Monkey15 Healthiest Countries in Asia
In this article, we will be taking a look at the 15 Healthiest Countries in Asia. You can skip our detailed analysis on the health market and directly head to the 5 Healthiest Countries in Asia. Growth and Investment Trends in the Asian Healthcare Market The global healthcare market, valued at $7.975 trillion in 2023, […]
Business WireAlto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants
MOUNTAIN VIEW, Calif., September 04, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a peer-review publication demonstrating baseline cognitive performance is not a moderator of response to standard-of-care antidepressants in patients with major depressive disorder (MDD). The analysis, titled "Baseline Cognition Is Not Associated With Depression O
